%0 Journal Article
%@ 2666-5247
%A Yates, Tom A
%A Grint, Daniel J
%D 2025
%F discovery:10206194
%I Elsevier BV
%J The Lancet Microbe
%T Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomes
%U https://discovery.ucl.ac.uk/id/eprint/10206194/
%Z Copyright © 2025 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/  4.0/).